Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

ADXS' LLM technology has not met investor or Big Pharma expectations, as evidenced by the less than impressive clinical trial data, investor exodus and final nail in the coffin of Amgen bailing after seeing early NEO trial data. Looking back a few years ago, Aduro experienced similar weak clinical results with its LLM technology and decided it was in the best interest of its shareholders to shut down the program. Ask yourself, why has ADXS not done the same and returned remaining cash to shareholders? I bet Ken Berlin can give you $500,000 reasons each year why he has not shut down the trials and returned cash to shareholders...